What 7 Analyst Ratings Have To Say About Health Catalyst
Portfolio Pulse from Benzinga Insights
Health Catalyst (NASDAQ:HCAT) has received mixed analyst ratings over the past three months, with 7 analysts offering views that range from bullish to somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings. The 12-month price targets show an average of $13.14, with a high of $16.00 and a low of $10.00, indicating a slight increase from the previous average target of $13.00. The company's financial performance shows positive revenue growth and a strong net margin, despite a high debt-to-equity ratio.
April 10, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Health Catalyst has received mixed analyst ratings but shows positive financial trends, including revenue growth and a strong net margin.
The mixed analyst ratings combined with positive financial performance indicators such as revenue growth and net margin suggest a cautiously optimistic outlook for HCAT in the short term. The slight increase in the average price target reflects a positive adjustment in market expectations, potentially leading to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100